We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
    next      view all

European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment to ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.


FDA Approves Kyprolis® (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma

Approval Expands Kyprolis Indication. Patients Treated With Kyprolis in Combination With Standard of Care Lived 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone in Pivotal Study


IMF's Black Swan Research Initiative Makes Inroads on Pathway to a Cure
The Black Swan Research Initiative® is moving ahead on all fronts, reports IMF Chairman Dr. Brian Durie in his blog this week. “The stage is set to include standardized MRD testing into clinical trials. And we continue to work on additional and simpler testing, such as a new blood test for early diagnosis and monitoring.” Also this week, a follow-up on possible connections between sitting too much and myeloma—but not what you’d expect! To read Dr. Durie’s blog, click HERE.

Members of International Myeloma Foundation’s Nurse Leadership Board Author Key Textbook for Nurses

Book Updates the First Comprehensive Review by and For Nurses 


Calling All Researchers: Submit Your Applications for 2016 IMF Grants
The IMF awards Brian D. Novis Junior and Senior Research Grants each year to "provide much-needed funding support for research projects being conducted by the best and the brightest in our field," according to IMF President Susie Novis. Funding grants since 1994 to honor IMF Co-Founder Brian D. Novis, the IMF has awarded more than 140 grants in 13 countries, which have opened the doors to new ideas and major advancements in treatments. Applications for 2016 grants are due by August 3rd. To submit an application, click HERE.

Expanded Access Program Opens for Daratumumab
Janssen Biotech, Inc. has announced the opening of a daratumumab expanded access program (EAP) at up to 40 medical centers for eligible US myeloma patients who have received at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent) or are double refractory to a proteasome inhibitor and an immunomodulatory agent. Daratumumab is currently an investigational human anti-CD38 monoclonal antibody treatment for multiple myeloma. To learn more about the EAP for daratumumab, contact the IMF InfoLine at (800) 452-2873 or email infoline@myeloma.org.

New Drug Application Filed with FDA for Oral Proteasome Inhibitor
Takeda has filed for FDA approval of ixazomib, which could become the first oral proteasome inhibitor for treating multiple myeloma. The New Drug Application (NDA) for ixazomib is based on the results of the phase III TOURMALINE-MM1 trial, which compared ixazomib to placebo—both given in 772 patients with relapsed or refractory myeloma. “If approved, ixazomib, with the convenience of once-a-week oral administration as well as promising efficacy, should provide a very meaningful advance for our patients,” said Dr. Paul Richardson, Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center Institute Physician at Dana-Farber Cancer Institute. Click HERE to read the announcement.

Is There a Tie Between Leisure Time Spent Sitting and Cancer Risks?
In his blog this week, IMF Chairman Dr. Brian Durie examines a new study in the July 2015 issue of “Cancer Epidemiology, Biomarkers & Prevention” suggesting that women who spend more leisure time sitting may be at a higher risk for multiple myeloma, breast and ovarian cancer. The higher risk was present even after taking into account BMI, physical activity, and other factors. The study found no association between sitting time and cancer risk in men. Click HERE to read his blog.

Clinical Trial Opens for New Generation Proteasome Inhibitor
Dr. Ola Landgren announced the opening of a new Phase I/II clinical trial at Memorial Sloan-Kettering Cancer Center for patients with relapsed and/or refractory myeloma. The trial will test a new proteasome inhibitor called VLX1570, which is given intravenously. VLX1570 was developed by researchers at Sweden’s Karolinska Institute. Memorial Sloan-Kettering has some funds available to help patients who demonstrate financial need with transportation and hotel costs. Click HERE to see the full trial listing. Please call the IMF InfoLine at (800) 452-2873 with any further questions.

What Is the Value of Treatment for Individual Cancer Patients?
Having myeloma is undeniably expensive. But will new systems of evaluating the cost and efficacy of treatment end up harming myeloma patients by mandating suboptimal care and eliminating access to needed drugs? In his blog this week, IMF Chairman Brian Durie examines these questions. “Individual patient value must be considered,” he writes. “But how do we do that?” Click HERE to read Dr. Durie’s blog.

    next      view all